USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015


Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

South Africa awards 5.9 billion-rand antivirals tender; Panacela Russian contract


The South African government has announced a 5.9 billion rand ($665 million) tender awarded to three…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesBiotechnologyCipla MedproCleveland BioLabsFinancialGeneralMylan LaboratoriesPanacela LabsRest of the WorldXenomycins

Mylan settles over Brovana; launches generic Boniva in UK and Italy


US generic drugs major Mylan (Nasdaq: MYL) has entered into an agreement with Sunovion Pharmaceuticals,…

Anti-Arthritics/RheumaticsBonivaBrovanaDainippon Sumitomo PharmaEuropeGenericsMarkets & MarketingMylan LaboratoriesNorth AmericaPatentsRespiratory and PulmonaryRocheSunovion

FDA approves first generics of Roche osteo drug Boniva


The US Food and Drug Administration yesterday approved the first generic versions of Boniva (ibandronate)…

Anti-Arthritics/RheumaticsApotexBonivaGenericsMylan LaboratoriesNorth AmericaOrchid HealthcareRegulationRoche

Gilead files patent infringement suit against Lupin over Ranexa; Mylan’s generic nabumetone cleared by FDA


Gilead Sciences says it has filed a law suit in US District Court in New Jersey, USA, against Indian-owned…

Anti-Arthritics/RheumaticsCardio-vascularGenericsGilead SciencesLupinMylan LaboratoriesNabumetoneNorth AmericaPatentsPharmaceuticalRanexa

Back to top